Tevogen Bio Holdings Inc
TVGN0.380USD
-0.001-0.26%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
74.95MMarket Cap
LossP/E TTM
More Details of Tevogen Bio Holdings Inc Company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Tevogen Bio Holdings Inc Info
Ticker SymbolTVGN
Company nameTevogen Bio Holdings Inc
IPO dateNov 04, 2021
CEOSaadi (Ryan)
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 04
Address15 Independence Boulevard, Suite #210
CityWARREN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07059
Phone16468078832
Websitehttps://tevogen.com/
Ticker SymbolTVGN
IPO dateNov 04, 2021
CEOSaadi (Ryan)
Company Executives of Tevogen Bio Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
10.45M
+7.73%
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
3.53M
+9.28%
Mr. Sadiq Khan
Mr. Sadiq Khan
Chief Commercial Officer
Chief Commercial Officer
1.17M
+20.63%
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director
Independent Director
641.77K
-21.90%
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
313.92K
-27.65%
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director
Independent Director
253.92K
-41.48%
Dr. Ryan Saadi, M.D.
Dr. Ryan Saadi, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Victor Sordillo
Mr. Victor Sordillo
Independent Director
Independent Director
--
--
Dr. Curtis Patton
Dr. Curtis Patton
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
10.45M
+7.73%
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
3.53M
+9.28%
Mr. Sadiq Khan
Mr. Sadiq Khan
Chief Commercial Officer
Chief Commercial Officer
1.17M
+20.63%
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director
Independent Director
641.77K
-21.90%
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
313.92K
-27.65%
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director
Independent Director
253.92K
-41.48%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Saadi (Ryan H)
62.67%
Patel (Manmohan)
6.72%
Desai (Kirti)
5.11%
Flomenberg (Neal)
1.78%
BlackRock Institutional Trust Company, N.A.
0.65%
Other
23.07%
Shareholders
Shareholders
Proportion
Saadi (Ryan H)
62.67%
Patel (Manmohan)
6.72%
Desai (Kirti)
5.11%
Flomenberg (Neal)
1.78%
BlackRock Institutional Trust Company, N.A.
0.65%
Other
23.07%
Shareholder Types
Shareholders
Proportion
Individual Investor
78.18%
Investment Advisor
1.68%
Investment Advisor/Hedge Fund
0.74%
Research Firm
0.09%
Bank and Trust
0.02%
Other
19.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
115
5.02M
2.55%
-6.01M
2025Q2
119
160.27M
86.89%
+1.70M
2025Q1
118
155.00M
115.37%
-16.72M
2024Q4
153
163.30M
93.29%
-39.38M
2024Q3
144
166.12M
95.10%
-39.63M
2024Q2
138
166.33M
103.53%
-38.91M
2024Q1
118
165.09M
105.20%
-36.99M
2023Q4
105
14.20M
68.79%
-44.82M
2023Q3
104
15.77M
75.02%
-42.16M
2023Q2
101
9.09M
32.79%
-42.84M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Saadi (Ryan H)
124.99M
63.54%
-20.00K
-0.02%
Aug 15, 2025
Patel (Manmohan)
13.35M
6.79%
+2.43M
+22.26%
Apr 30, 2025
Desai (Kirti)
10.45M
5.31%
+750.00K
+7.73%
Jun 27, 2025
Flomenberg (Neal)
3.53M
1.8%
+300.00K
+9.28%
Jun 27, 2025
BlackRock Institutional Trust Company, N.A.
1.22M
0.62%
+573.09K
+88.87%
Jun 30, 2025
Khan (Sadiq)
1.17M
0.59%
+200.00K
+20.63%
Jun 27, 2025
The Vanguard Group, Inc.
1.09M
0.55%
+50.31K
+4.83%
Jun 30, 2025
Patton (Curtis L)
1.03M
0.52%
-180.00K
-14.88%
Apr 30, 2025
Feike (Jeffrey L)
641.77K
0.33%
-180.00K
-21.90%
Apr 30, 2025
Geode Capital Management, L.L.C.
542.02K
0.28%
+55.63K
+11.44%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0%
Proshares Ultra Russell 2000
0%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Micro-Cap ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Biotechnology ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tevogen Bio Holdings Inc?
The top five shareholders of Tevogen Bio Holdings Inc are:
Saadi (Ryan H) holds 124.99M shares, accounting for 63.54% of the total shares.
Patel (Manmohan) holds 13.35M shares, accounting for 6.79% of the total shares.
Desai (Kirti) holds 10.45M shares, accounting for 5.31% of the total shares.
Flomenberg (Neal) holds 3.53M shares, accounting for 1.80% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.22M shares, accounting for 0.62% of the total shares.
Saadi (Ryan H) holds 124.99M shares, accounting for 63.54% of the total shares.
Patel (Manmohan) holds 13.35M shares, accounting for 6.79% of the total shares.
Desai (Kirti) holds 10.45M shares, accounting for 5.31% of the total shares.
Flomenberg (Neal) holds 3.53M shares, accounting for 1.80% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.22M shares, accounting for 0.62% of the total shares.
What are the top three shareholder types of Tevogen Bio Holdings Inc?
The top three shareholder types of Tevogen Bio Holdings Inc are:
Saadi (Ryan H)
Patel (Manmohan)
Desai (Kirti)
Saadi (Ryan H)
Patel (Manmohan)
Desai (Kirti)
How many institutions hold shares of Tevogen Bio Holdings Inc (TVGN)?
As of 2025Q3, 115 institutions hold shares of Tevogen Bio Holdings Inc, with a combined market value of approximately 5.02M, accounting for 2.55% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -84.34%.
What is the biggest source of revenue for Tevogen Bio Holdings Inc?
In --, the -- business generated the highest revenue for Tevogen Bio Holdings Inc, amounting to -- and accounting for --% of total revenue.
